- Home
- MEGI vs IVA Comparison
MEGI vs IVA Comparison
Compare MEGI & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGI
- IVA
- Stock Information
- Founded
- MEGI 2021
- IVA 2011
- Country
- MEGI United States
- IVA France
- Employees
- MEGI N/A
- IVA N/A
- Industry
- MEGI Investment Managers
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- MEGI Finance
- IVA Health Care
- Exchange
- MEGI Nasdaq
- IVA Nasdaq
- Market Cap
- MEGI 749.0M
- IVA 769.0M
- IPO Year
- MEGI N/A
- IVA 2020
- Fundamental
- Price
- MEGI $14.53
- IVA $5.55
- Analyst Decision
- MEGI
- IVA Strong Buy
- Analyst Count
- MEGI 0
- IVA 6
- Target Price
- MEGI N/A
- IVA $15.33
- AVG Volume (30 Days)
- MEGI 178.0K
- IVA 71.5K
- Earning Date
- MEGI 01-01-0001
- IVA 09-26-2025
- Dividend Yield
- MEGI 11.40%
- IVA N/A
- EPS Growth
- MEGI N/A
- IVA N/A
- EPS
- MEGI N/A
- IVA N/A
- Revenue
- MEGI N/A
- IVA $14,591,573.00
- Revenue This Year
- MEGI N/A
- IVA $80.35
- Revenue Next Year
- MEGI N/A
- IVA N/A
- P/E Ratio
- MEGI N/A
- IVA N/A
- Revenue Growth
- MEGI N/A
- IVA N/A
- 52 Week Low
- MEGI $10.63
- IVA $1.53
- 52 Week High
- MEGI $14.89
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- MEGI 58.98
- IVA 59.79
- Support Level
- MEGI $14.26
- IVA $5.21
- Resistance Level
- MEGI $14.58
- IVA $5.78
- Average True Range (ATR)
- MEGI 0.15
- IVA 0.37
- MACD
- MEGI 0.00
- IVA -0.03
- Stochastic Oscillator
- MEGI 78.05
- IVA 51.78
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.